The characterization of receptor binding kinetics of preclinical drug candidates is now becoming more readily appreciated as a key addition to the discovery process. Benefits of studying kinetics include increased understanding of prolonged duration of action, ability to differentiate between different pre-clinical candidates and in the understanding of differential in vivo efficacies. At present these effects are dependent on the suitability of a radioligand and therefore limits which receptors and molecules can be investigated.
|Number of pages
|Published - 2014
|ASCEPT-MPGPCR 2014 - Melbourne Convention and Exhibition Centre, Melbourne, Australia
Duration: 7 Dec 2014 → 11 Dec 2014
|7/12/14 → 11/12/14